DOCSLIB.ORG

SANJEEVAK 1586083 01/08/2007 MANOJ ANANT JOSHI Trading As ;AKSHAY PHARMA REMEDIES KAVRANA HOUSE, OPP

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
SANJEEVAK 1586083 01/08/2007 MANOJ ANANT JOSHI Trading As ;AKSHAY PHARMA REMEDIES KAVRANA HOUSE, OPP Trade Marks Journal No: 1836 , 12/02/2018 Class 5 SANJEEVAK 1586083 01/08/2007 MANOJ ANANT JOSHI trading as ;AKSHAY PHARMA REMEDIES KAVRANA HOUSE, OPP. COTTON GREEN RLY. STN. MUMBAI-400033. MANUFACTURE & MERCHANT INDIAN NATIONAL Used Since :31/01/2001 MUMBAI MEDICINAL PREPARATIONS. 537 Trade Marks Journal No: 1836 , 12/02/2018 Class 5 SEPTIGARD 1741718 08/10/2008 INDERJIT SINGH trading as ;INDERJIT SINGH B-104 , SWASTHYA SINGH , NEW DELHI -92 MERCHANTS & MANUFACTUERERS Address for service in India/Agents address: MAHTTA & CO. 43 - B/3, MAHTTA HOUSE,UDHAM SINGH NAGAR, LUDHIANA - 141 001, (PUNJAB). Proposed to be Used DELHI MEDICINAL & PHARMACEUTICAL PREPARATIONS. 538 Trade Marks Journal No: 1836 , 12/02/2018 Class 5 FAIR & BEAUTY 1803779 08/04/2009 GALPHA LABORATORIES LIMITED 221, Kanakia Zillion, E Wing Bandra Kurla Complex Annex LBS Marg & CST Road Junction Kurla West MUMBAI 400070 MANUFACTURERS AND MERCHANTS INDIAN NATIONAL Used Since :15/11/2007 MUMBAI PHARMACEUTICAL AND MEDICINAL PREPARATIONS AND SUBSTANCES 539 Trade Marks Journal No: 1836 , 12/02/2018 Class 5 O-BAMA 1815900 08/05/2009 KREMOINT PHARMA PVT. LTD. 151/5, SHRI KRISHNA DARSHAN, GARODIA NAGAR, GHATKOPAR (E), BOMBAY-400 077. MANUFACTURERS AND MERCHANTS. A CORPORATE ENTITY INCORPORATED IN INDIA UNDER THE COMPANIES ACT 1956. Address for service in India/Attorney address: KRISLAW CONSULTANTS BUILDING NO.4, C/104, SHANKESHWAR PALMS, BEHIND MODEL SCHOOL, KUMBHARKHANPADA, SUBHASH ROAD, DOMBIVILI(W) 421202 Used Since :02/05/2009 MUMBAI PHARMACETICAL AND MEDICINAL PREPARATIONS. 540 Trade Marks Journal No: 1836 , 12/02/2018 Class 5 AYUSHAKTI D-VYRO 1815928 08/05/2009 SMITA NARAM BUNGALOW NO.31, NEXT TO M. D. BUNGALOW NO. 25, ROYAL PALM ESTATE, AAREY COLONY, GOREGAON(EAST), MUMBAI-400065 MANUFACTURER MERCHANT INDIAN NATIONAL Address for service in India/Agents address: USHA A. CHANDRASEKHAR. 3-E1, COURT CHAMBERS, NEW MARINE LINES ROAD, MUMBAI - 400 020. Used Since :08/05/2009 MUMBAI HERBAL AND AYURVEDIC TONICS, AYURVEDIC MEDICINAL PREPARATIONS, FOOD FOR CHILDREN AND INVALIDS, MEDICINAL TOPICAL APPLICATIONS, MEDICATED SKIN CREAMS, FREE REDICAL AGENTS AND STIMULANTS, DIETARY SUPPLEMENTS, HERBAL FOOD SUPPLEMENTS AND FOOD SUPPLEMENTS OF HERBO-MINERAL ORIGIN INCLUDED IN CLASS 5. 541 Trade Marks Journal No: 1836 , 12/02/2018 Class 5 1885392 17/11/2009 MARYAM PHARMACEUTICALS PVT. LTD trading as ;MARYAM PHARMACEUTICALS PVT. LTD D-1 316 AMBEDKAR VIHAR JOHRIPUR EXTENSION JAWAHER NAGAR DELHI-94 MERCHANTS & MANUFACTURERS A COMPANY INCORPORATED UNDER THE& COMPANIES ACT 1956 Address for service in India/Agents address: FIN CENTURION CO. U-55A, IST FLOOR, STREET NO.4, U BLOCK, SHAKARPUR, DELHI-110092 Used Since :20/08/2008 DELHI PHARMACEUTICAL,MEDICINAL AND VETERINARY PREPARATION AS PER CLASS-5 542 Trade Marks Journal No: 1836 , 12/02/2018 Class 5 CORCEF TAZO 1914316 28/01/2010 SANICOR LIFE SCIENCE PVT. LTD 128/97 K BLOCK KIDWAI NAGAR KANPUR-202011 U.P MANUFCTURER & MERCHANTS Address for service in India/Agents address: ANSHUL & CO. H-882, SATYAM VIHAR, AVAS VIKAS COLONY, KALYANPUR, KANPUR-208017, U.P. Used Since :14/01/2010 DELHI PHARMACEUTICAL VETERINARY MEDICINS FOR VETERINARY USES INCLUDED IN CLASS 05. 543 Trade Marks Journal No: 1836 , 12/02/2018 Class 5 HIPOD 1945780 05/04/2010 SHOWKAT AHAMED NASEER AHMED trading as ;XGEN LIFE SCIENCES HOUSE NO-107 PARAY BUILDING KAK-SARAI SRI NAGAR KASHMIR-190010 MANUFACTURERES AND MERCHANTS Address for service in India/Agents address: BANSAL & BANSAL 210, JOP PLAZA (OPP. MC DONALD"S) P-2, SECTOR-18, NOIDA-201301, NCR DELHI. Used Since :01/04/2008 DELHI PHARMACEUTICAL MEDICINES. 544 Trade Marks Journal No: 1836 , 12/02/2018 Class 5 CAPE 1980379 16/06/2010 M/S MEDIZEN MARKETING 405-B WING, SAGAR TECH PLAZA, SAKINAKA JUNCTION, ANDHERI (EAST), MUMBAI-400072 MANUFACTURER AND MERCHANTS A PRIVATE LIMITED COMPANY Used Since :01/01/2009 MUMBAI PHARMACEUTICAL PRODUCTS. 545 Trade Marks Journal No: 1836 , 12/02/2018 Class 5 ISODILAN 1984516 24/06/2010 VARINDER SHARMA RAKESH KAPOOR N.S. THAKUR NITIN BHARTI trading as ;AXNTURE HEALTH CARE 4, B - BLOCK MARKET NEAR HIG FLATS, NEW AMRITSAR, G.T. ROAD, AMRITSAR MERCHANTS & MANUFATURERS Address for service in India/Agents address: LALJI ADVOCATES A - 48, (LALJI HOUSE) YOJNA VIHAR, DELHI -110092. Used Since :01/04/2007 DELHI MEDICINAL AND PHARMACEUTICAL PREPARATIONS. 546 Trade Marks Journal No: 1836 , 12/02/2018 Class 5 1995230 19/07/2010 AMIT KUMAR UPADHYAY trading as ;BASIC AYURVEDA 2C-212, VASHUNDHARA ,GHAZIABAD,( U.P) MANUFACTURING, TRADING AND EXPORT Address for service in India/Agents address: S.P. SINGH, ADV. B-77, B.G.S. BLOCK, TIS HAZARI COURTS, DELHI-110054 Used Since :01/01/2006 DELHI Herbal/ Ayurvedic and medicinal preparations. Syrups, food supplements tablets and medicines included in class 5 547 Trade Marks Journal No: 1836 , 12/02/2018 Class 5 AAMLA BITE 1995232 19/07/2010 AMIT KUMAR UPADHYAY trading as ;BASIC AYURVEDA 2C-212, VASHUNDHARA ,GHAZIABAD,( U.P) MANUFACTURING, TRADING AND EXPORT Address for service in India/Agents address: S.P. SINGH, ADV. B-77, B.G.S. BLOCK, TIS HAZARI COURTS, DELHI-110054 Used Since :01/01/2007 DELHI Herbal/ Ayurvedic and medicinal preparations^ Syrups, food supplements and medicines included in class 5 548 Trade Marks Journal No: 1836 , 12/02/2018 Class 5 ALOE AMLA 50-50 1995233 19/07/2010 AMIT KUMAR UPADHYAY trading as ;BASIC AYURVEDA 2C-212, VASHUNDHARA ,GHAZIABAD,( U.P) MANUFACTURING, TRADING AND EXPORT Address for service in India/Agents address: S.P. SINGH, ADV. B-77, B.G.S. BLOCK, TIS HAZARI COURTS, DELHI-110054 Used Since :01/01/2007 DELHI Medicinal juices and tablets 549 Trade Marks Journal No: 1836 , 12/02/2018 Class 5 ALOE VERA JUICE-H 1995235 19/07/2010 AMIT KUMAR UPADHYAY trading as ;BASIC AYURVEDA 2C-212, VASHUNDHARA ,GHAZIABAD,( U.P) MANUFACTURING, TRADING AND EXPORT Address for service in India/Agents address: S.P. SINGH, ADV. B-77, B.G.S. BLOCK, TIS HAZARI COURTS, DELHI-110054 Used Since :01/01/2007 DELHI Medicinal juices and tablets” 550 Trade Marks Journal No: 1836 , 12/02/2018 Class 5 CALCI YOG 1995236 19/07/2010 AMIT KUMAR UPADHYAY trading as ;BASIC AYURVEDA 2C-212, VASHUNDHARA ,GHAZIABAD,( U.P) MANUFACTURING, TRADING AND EXPORT Address for service in India/Agents address: S.P. SINGH, ADV. B-77, B.G.S. BLOCK, TIS HAZARI COURTS, DELHI-110054 Used Since :01/01/2006 DELHI ”Calcium tablet and powder" 551 Trade Marks Journal No: 1836 , 12/02/2018 Class 5 TONEX 2020130 08/09/2010 PARK PHARMACEUTICALS 272 INDUSTRIAL AREA PHASE-2 PANCHKULA -134113 HARYANA MERCHANTS & MANUFACTURERS Address for service in India/Agents address: RAHUL RAJPUT. B-336, BHAI RANDHIR SINGH NAGAR, LUDHIANA - 141 004 PUNJAB. Used Since :01/01/1994 DELHI MEDICINAL & PHARMACEUTICAL PREPARATIONS 552 Trade Marks Journal No: 1836 , 12/02/2018 Class 5 EYEVISION 2025095 18/09/2010 ASHOK KUMAR RAI trading as ;Arti Pharmaceuticals. D-4 Shivam Complex, Gandhi Park Gorakhpur 273016 (UP) ARTI PHARMACEUTICALS D-4, SHIVAM COMPLEX GANDHI PARK GORKHPUR, U.P. Marketing and Trading Address for service in India/Attorney address: DR S K MARWAH 3290 Sector 24 D Chandigarh 160023 Used Since :07/06/2009 DELHI Medicines for human purpose 553 Trade Marks Journal No: 1836 , 12/02/2018 Class 5 2034962 08/10/2010 SHRIKA BIOTECH PVT. LTD PAMA COMPOUND DLW, SHIVDASPUR ROAD, LAHARTARA, VARANASI,U.P-221013 MANUFACTURING & TRADING Address for service in India/Attorney address: TYAGI CERTIFICATIONS SERVICES PVT. LTD. 3/112, LALITA PARK, LAXMI NAGAR, DELHI-92 Used Since :01/06/2010 DELHI ALL KINDS OF MEDICINE & PHARMACEUTICAL PREPARATIONS AND FOOD SUPPLEMENTS INCLUDED IN CLASS (05) 554 Trade Marks Journal No: 1836 , 12/02/2018 Class 5 PHOSZEAL 2046157 28/10/2010 NEOZEAL LIFECARE P LTD. 37 B, UMANG MAHANAGAR, PART - 1, BAREILLY - 243006, U.P MANUFACTURING, MARKETING & TRADING. AN INDIAN COMPANY INCORPORATED UNDER THE COMPANY ACT 1956. Address for service in India/Attorney address: DR S K MARWAH 3290 Sector 24 D Chandigarh 160023 Used Since :09/09/2006 DELHI MEDICINES. 555 Trade Marks Journal No: 1836 , 12/02/2018 Class 5 CALCIKID 2047819 01/11/2010 AMIT THAKUR 3962, NEETA STREET, MEHNA CHOWK ,BHATINDA PB. MANUFACTURER & TRADER Address for service in India/Attorney address: RAMESH K. GAUTAM & ASSOCIATES H.N. 451, OPP. BSNL TOWER, AMBEDKAR ROAD, ARTHALA, MOHAN NAGAR, GHAZIABAD-201007 (U.P) Used Since :30/10/2010 DELHI MEDICINAL & PHARMACEUTICALS & AYURVEDIC PREPARATIONS 556 Trade Marks Journal No: 1836 , 12/02/2018 Class 5 SMARTAMLA 2060706 29/11/2010 N K GARG trading as ;HEALTH VITALS CABIN NO 10 & 11 SCO 867 FF NAC MANI MAJRA CHANDIGARH MANUFACTURING MARKETING & TRADING Address for service in India/Attorney address: DR.S.K.MARWAH 292 Model Town Ambala City 134003 (Haryana) Used Since :15/01/2007 DELHI HEALTH SUPPLIMENTS 557 Trade Marks Journal No: 1836 , 12/02/2018 Class 5 CAMPAIN 2068343 15/12/2010 FRONTIAGO LIFESCIENCES PVT,LTD. 101/102 RUTU BUSINESS PARK, OFF. L.B.S. MARG, THANE (WEST) 400601. MAHARASHTRA. (INDIA). MANUFACTURER AND MERCHANT PRIVATE LIMITED COMPANY INCORPORATED IN INDIAN COMPANIES ACT, 1956. Address for service in India/Attorney address: CHANDRAKANT & ASSOCIATE CHHATRAPATI SHIVAJI RAJE COMPLEX, BUILDING NO.6, FLAT NO.5, GROUND FLOOR, OPP. EKTA NAGAR, KANDIVALI (WEST), MUMBAI-400 067. Used Since :01/09/2010 MUMBAI MEDICINAL AND PHARMACEUTICAL PREPARATIONS 558 Trade Marks Journal No: 1836 , 12/02/2018 Class 5 2070697 20/12/2010 ACHAL KUMAR MATHUR. trading as ;WHIZKID FORMULATION 160 B A-1 PASCHIM VIHAR MAA SHAKTI APARTMENT NEW DELHI MANUFACTRING AND TRADING Address for service in India/Attorney address: TYAGI CERTIFICATIONS SERVICES PVT. LTD. 3/112, LALITA PARK, LAXMI NAGAR, DELHI-92 Used Since :10/11/2006 DELHI PHARMACEAUTICAL PREPARATIONS, MEDICINES. 559 Trade Marks Journal No: 1836 , 12/02/2018 Class 5 2070699 20/12/2010 ACHAL KUMAR MATHUR.
Load more

  1192
Copy Link
Recommended publications
  • Hy Sun Missed the Pharma Rally: the Answer Is Hidden in a Bet Many Failed — Speciality Drugs - the Economic Times
    12/3/2020 Sun Pharma: Why Sun missed the pharma rally: the answer is hidden in a bet many failed — speciality drugs - The Economic Times Home ETPrime Markets News Industry RISE Politics Wealth MF Tech Jobs Opinion NRI Panache ET NOW More Aayush English Edition | E-Paper Tech Consumer Markets Corporate Governance Telecom + OTT Auto + Aviation Pharma Fintech + BFSI Economy Infra Environment Energy Business News › Prime › Pharma › Why Sun missed the pharma rally: the answer is hidden in a bet many failed — speciality drugs Getty Images MARKETS hy Sun missed the pharma rally: the answer is hidden in a bet many failed — speciality drugs Dilip Shanghvi, founder and managing director, Sun Pharmaceuticals Synopsis Sun Pharma is the only Indian company to have made some inroads into speciality drugs. What worries investors is high investments and uncertainties over ramp up in revenue. The stock can still see upside because of its current valuations, strong India business, and any positive surprises in US generic business. But it is crucial that its speciality bet pays off. BACK TO TOP https://economictimes.indiatimes.com/prime/pharma-and-healthcare/why-sun-missed-the-pharma-rally-the-answer-is-hidden-in-a-bet-many-failed-spe… 1/11 12/3/2020 Sun Pharma: Why Sun missed the pharma rally: the answer is hidden in a bet many failed — speciality drugs - The Economic Times Home ETPrime Markets NeCwasllI nitd uas trbyleRssISiEngP oilniti cdsisWgeuailthse fMoFr tTheceh InJodbisanOpinion NRI Panache ET NOW More pharmaceutical industry. The stocks of pharma companies have been on a tear since the beginning of the Covid-19 crisis.
    [Show full text]
  • Pharmaceuticals Stellar Quarter; Healthy Outlook Sector Update
    Pharmaceuticals Stellar quarter; Healthy Outlook Sector Update Q2FY2021 was yet another stellar quarter for pharmaceutical companies under Q2FY2021 Results Review Sharekhan’s pharma universe. The quarter witnessed a sustained improvement in Sector: Pharmaceuticals the US business while the domestic business showed signs of improvement. The overall plant utilization levels during Q2FY2021 were at normal levels (as against Sector View: Positive relatively low utilization levels in previous quarter), thus yielding costs benefits. For the quarter, the pharma companies delivered revenue growth of 8.8% y-o-y, while sequentially as well it clocked a growth of 8.3%. Topline performance was better than estimates and was driven by sturdy performance of the US business, while the India operations also grew a decent pace. Growth in the base business, stabilizing price erosion and new launches led to the growth in US business, while in India business, companies with a relatively higher share of chronic business grew strongly and outperformed the industry. Select players such as Aurobindo, Cadila and Cipla reported strong 12.5%, 18% and 10% y-o-y growth respectively in the US business. Divis labs also reported a strong 21% y-o-y growth in the topline backed by a strong performance in the API segment, while Laurus labs posted a 60% revenue Our active coverage universe growth on the back of an impressive growth in the formulations segment. Operating CMP PT profit for the universe increased sharply by 21% y-o-y. Operating margin also Companies Reco. (Rs) (Rs) expanded by 251 bps y-o-y, better the expected 150 bps y-o-y expansion.
    [Show full text]
  • Ajanta Pharma Limited
    AJANTA PHARMA LIMITED CIN : L24230MH1979PLC022059 Registered & Corporate Office: ‘Ajanta House’, 98 Govt Industrial Area, Charkop, Kandivli (West), Mumbai - 400 067, Maharashtra, India Tel.: +91 22 6606 1000, Fax: +91 22 6606 1200 | E-mail: [email protected] | Website: www.ajantapharma.com POST BUYBACK PUBLIC ANNOUNCEMENT FOR THE ATTENTION OF EQUITY SHAREHOLDERS/ BENEFICIAL OWNERS OF EQUITY SHARES OF AJANTA PHARMA LIMITED This public announcement (the “Post Buyback Public Announcement”) is being made pursuant to the provisions of Regulation 24(vi) of the Securities and Exchange Board of India (Buy-Back of Securities) Regulations, 2018, for the time being in force including any statutory modifications and amendments from time to time (the “Buyback Regulations”). This Post Buyback Public Announcement should be read in conjunction with the Public Announcement dated November 4, 2020 which was published on November 5, 2020 (the “Public Announcement”) and the letter of offer dated November 25, 2020 (the “Letter of Offer”) issued in connection with the Buyback. The terms used but not defined in this Post Buyback Public Announcement shall have the same meanings as assigned in the Public Announcement and the Letter of Offer. 1. THE BUYBACK 1.1 Ajanta Pharma Limited (the “Company”) had announced the Buyback of not exceeding 7,35,000 (Seven Lakh Thirty Five Thousand) fully paid-up equity shares of face value of ₹2 each (“Equity Shares”) from all the existing shareholders / beneficial owners of Equity Shares as on the record date (i.e. Friday, November 13, 2020), on a proportionate basis, through the “Tender Offer” process at a price of ₹1,850/- (Rupees One Thousand Eight Hundred and Fifty Only) per Equity Share payable in cash for an aggregate consideration not exceeding ₹ 135,97,50,000 (Rupees One Hundred Thirty Five Crores Ninety Seven Lakhs and Fifty Thousand only) excluding the Transaction Costs (“Buyback Offer Size”).
    [Show full text]
  • Saturday, 23Rd August 2014 Index Levels : Market Trend (Nifty)
    ` Saturday, 23rd August 2014 Index Levels : Market Trend (Nifty): Trend Reversal Point INDEX SUPPORTS RESISTANCES Period Current Trend (TRP)Nifty close basis NIFTY# 7930/8000/8090 Short Term Trend UP DOWN BELOW 7750 (7913.20) 7850/7760 SENSEX# 26250/26000 26550/26700/27200 Medium Term UP DOWN BELOW 7650 (26419.55) ITE-35* -------- -------- Long Term Trend UP DOWN BELOW 6500 (10239.68) ND #as on 22 August 2014 Imtiaz Merchant’s Best Picks: Indices: CURRENT Domestic COMPANY NAME SIZE SECTOR Close Points % Chg PRICE Indices Large Cipla Health Care 499 BSE Sensex 26419.55 59.44 0.23 % Cap Large Industrials and UPL 338 Nifty 7913.20 22.10 0.28 % Cap Capital Goods ITE Shariah 10239.68 42.83 0.42 % 35* S&P CNX 500 1919.15 4.92 0.12 % Note: (Buying should be done from a medium to long term perspective) Shariah Advance/ Advance Decline AD Un- Market Brief Decline Ratio Changed BSE 1462 1572 0.93:1 114 On the back of positive global cues and some NSE 693 782 0.89:1 60 reform announcements by the Union Shariah Government, the markets on Friday ended the Universe*** 291 269 1.08:1 15 day and the week on positive note; Auto, Info. Technology and Health Care sectors were the flavor of the week. The undertone appears to Global Indices Close Points % Chg be bullish. All the trends are up. More reform Dow Jones* 16979.13 60.36 0.36% announcements from the Govt. and good NASDAQ* 4526.48 5.62 0.12% corporate results will further fuel the rally and FTSE* 6755.48 22.18 0.33% the Nifty is likely to see the 8000 level soon.
    [Show full text]
  • Inner 25 India Pharma & Healthcare Fund
    Modera erate tely Mod High to e H w at ig o er h L d o M V e r y w H Tata India Pharma & Healthcare Fund o i L g (An open ended equity scheme investing in Pharma and Healthcare Services Sector) h Riskometer Investors understand that their principal As on 30th June 2021 PORTFOLIO will be at Very High Risk INVESTMENT STYLE Company name No. of Market Value % of Company name No. of Market Value % of Primarily focuses on investment in at least 80% of its net Shares Rs. Lakhs Assets Shares Rs. Lakhs Assets assets in equity/equity related instruments of the companies in the Pharma & Healthcare sectors in India. Equity & Equity Related Total 55184.24 97.88 Glenmark Pharmaceuticals Ltd. 167000 1089.76 1.93 INVESTMENT OBJECTIVE Healthcare Services Sanofi India Ltd. 13000 997.39 1.77 The investment objective of the scheme is to seek long Apollo Hospitals Enterprise Ltd. 70500 2551.99 4.53 Gland Pharma Ltd. 19662 673.29 1.19 term capital appreciation by investing atleast 80% of its Fortis Healthcare Ltd. 795000 1935.03 3.43 Laurus Labs Ltd. 90000 619.79 1.10 net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in Syngene International Ltd. 265000 1545.75 2.74 India.However, there is no assurance or guarantee that the investment objective of the Scheme will be Narayana Hrudayalaya Ltd. 301420 1483.74 2.63 Other Equities^ 1186.14 2.10 achieved.The Scheme does not assure or guarantee any Metropolis Healthcare Ltd.
    [Show full text]
  • MF 35 Fund One Pager
    BR“BuyS RightT : BSit TightR” ST BRSnowT Bin fourRS differentTBRS colorsTBRS BRSTBRSTBRSTBR Motilal Oswal MOSt Focused Invests in enduring B25 RFund STBRSTBwRealth creaStors T Motilal Oswal MOSt Focused Invests in emerging BMidcapR 30 Fund TBRwealth creators T BRSTBSRSTBRSTBSRS Motilal Oswal MOSt Focused Invests in emerging and BMulticapRS 35 FundT BRSTBRenduringST wealthB creatorRs Lock in fund that invests Motilal Oswal MOSt Focused in wealth creators BLongR Term SFund TBRSTBplusR Saves TSax T BR TBR T BRSTBSRSTBRSTBSRS Focused Low Churn QGLP No load BRSTBPortfolioRSTBPortfolioRSTStocksBR BRSInvesTt nowB to addR colorSs Tto yourB porRolioST BRSCall:T 1800-200-6626B | SMS:R FOCUSS to 575753T BRSTBRS Website: www.motilaloswalmf.com Our Investment Philosophy The recommended way to create Wealth from equity- 'Buy Right : Sit Tight' At Molal Oswal Asset Management Company (MOAMC), our investment philosophy and invesng style is centered on 'Buy Right: Sit Tight‘ principal. ‘Buy Right' means buying quality companies at a reasonable price and 'Sit Tight' means staying invested in them for a longer me to realise the full growth potenal of the stocks. Buy Right Stock Characteristics Sit Tight Approach QGLP ‘Q’uality denotes quality of the business and Buy and Hold: We are strictly buy and hold management investors and believe that picking the right ‘G’rowth denotes growth in earnings and business needs skill and holding onto these sustained RoE businesses to enable our investors to benefit from the entire growth cycle needs even more ‘L’ongevity denotes longevity of the skill. competitive advantage or economic moat of the business Focus: Our portfolios are high conviction portfolios with 20 to 25 stocks being our ideal ‘P’rice denotes our approach of buying a good n u m b e r.
    [Show full text]
  • CARE Ratings Ltd
    CARE/HO/RL/2020-21/2749 Mr. Arvind Agrawal Chief Financial Officer Ajanta Pharma Limited Ajanta House, Charkop, Kandivali (W), Mumbai-400067 October 1, 2020 Confidential Dear Sir, Credit rating for bank facilities On the basis of recent developments including operational and financial performance of your company for FY20 (audited) and Q1FY21 (provisional), our Rating Committee has reviewed the following ratings: Facilities Amount Rating1 Rating (Rs. crore) Action Long-term/Short-term Bank 55.00 CARE AA; Stable/CARE A1+ Facilities (reduced from 87.50) (Double A; Outlook: Stable/A Reaffirmed One Plus) Total 55.00 (Rs. Fifty Five crore only) 2. Refer Annexure 1 for details of rated facilities. 3. The rationale for the rating will be communicated to you separately. A write-up (press release) on the above rating is proposed to be issued to the press shortly, a draft of which is enclosed for your perusal as Annexure-2. We request you to peruse the annexed document and offer your comments if any. We are doing this as a matter of courtesy to our clients and with a view to ensure that no factual inaccuracies have inadvertently crept in. Kindly revert as early as possible. In any case, if we do not hear from you by October 5, 2020 we will proceed on the basis that you have no any comments to offer. 4. CARE reserves the right to undertake a surveillance/review of the rating from time to time, based on circumstances warranting such review, subject to at least one such review/surveillance every year. 5.
    [Show full text]
  • In the United States District Court for the Eastern District of Michigan
    Case 2:10-cv-10656-AC-MKM Document 1 Filed 02/16/10 Page 1 of 11 IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF MICHIGAN ABBOTT LABORATORIES and ) ABBOTT RESPIRATORY LLC, ) ) Plaintiffs, ) ) C.A. No. 2:10-cv-10656 v. ) ) SUN PHARMACEUTICAL INDUSTRIES, LTD. ) and SUN PHARMA GLOBAL FZE, ) ) Defendants. ) COMPLAINT Plaintiffs Abbott Laboratories and Abbott Respiratory LLC (collectively, “Abbott”), by their attorneys, hereby allege as follows: Nature of the Action This is an action for patent infringement of U.S. Patent Nos. 6,080,428 (“the ‘428 patent”) and 6,469,035 (“the ‘035 patent”), arising under the patent laws of the United States, Title 35, United States Code, 35 U.S.C. §§ 271 and 281. This action relates to Abbreviated New Drug Application (“ANDA”) No. 20-0484 filed by Sun Pharma Global FZE (“Sun FZE”) with the U.S. Food and Drug Administration (“FDA”) for approval to market 500 mg and 1000 mg niacin extended-release tablets that are generic versions of the 500 mg and 1000 mg strength versions of Abbott’s highly successful NIASPAN® drug product. Related Actions The present action is related to an identical patent infringement action pending before the United States District Court for the District of Delaware, Abbott Laboratories and Abbott Case 2:10-cv-10656-AC-MKM Document 1 Filed 02/16/10 Page 2 of 11 Respiratory, LLC v. Sun Pharmaceutical Industries, Ltd. and Sun Pharmaceuticals, Inc. (C.A. 10-cv-112) (the “Delaware Sun Action”), pertaining to ANDA No. 20-0484 filed by Sun FZE for approval to market generic versions of Abbott’s 500 mg and 1000 mg strength NIASPAN® tablets.
    [Show full text]
  • INDIA OUTBOUND T&A Consulting Volume 6 Issue 4 3Rd April, 2017
    INDIA OUTBOUND T&A Consulting Volume 6 Issue 4 3rd April, 2017 As the Financial Year comes to an end so has an eventful The trend among Indian pharma firms of “building brands“ quarter. With the liquidity shock of de-monetization having been continued, with Aurobindo Pharma adding to its portfolio of managed and a healthy, albeit counter-intuitive GDP data biosimilars acquired from a Swiss firm and leveraging market (annualised GDP growth at 7.0% for Oct-Dec Qtr) having access across specialized therapeutic segments provided by a established the soundness of macroeconomic fundamentals, the Portugese generics firm. Also active was Piramal Enterprises, high for the current Government came in the form of results for acquiring the drug portfolio of UK-based Mallinckrodt LLC to reach a the Uttar Pradesh elections. The win for the Bhartiya Janata targeted segment across eight European markets. Sun Pharma and Party in U.P. has consolidated its hold at the Centre and across Zydus Cadilla were active in North America, with Zydus acquiring a India. What that means going forward is further stability on US drug firms for a sizeable cheque to bolster its specialty India’s policy front. Case in point has been the Government’s pharmaceuticals segment whilst Sun Pharma acquired a small push in the on-going budget session of Parliament to meet the Canadian drug discovery firm. On the IT front, the bigger boys of Indian July 2017 deadline in implementing the Goods and Services IT were active acquiring assets in Latin America and their preferred market Tax. The outbound investment story nevertheless continues - United States.
    [Show full text]
  • Chairperson Speech 2021-Final.Cdr
    Unwavering Purpose Chairperson’s AGM Speech 43rd Annual General Meeting Friday, July 23, 2021, Bengaluru, India Kiran Mazumdar-Shaw Executive Chairperson 2 Dear Shareholders, As we connued with our operaons, we also focused on protecng our people and ensuring It gives me great pleasure to welcome you their health and well-being. We invested in to the 43rd Annual General Meeting of implemenng strict safety protocols and your company. regularly engaged with our people to keep them movated. The leadership team constantly The pharmaceutical and healthcare monitored the fast-evolving situaon and took industry's fight against COVID-19 data-driven decisions for operaonal planning across our facilies. intensified over the past year as fresh waves of infections hit many countries REALIZING THE BIOSIMILARS PROMISE around the world. As the pandemic left societies and economies in disarray, Our Biosimilars business revenue at Rs 28,002 million, recorded a growth of 21% in FY21. We biotechnology-led companies quickly commercialized our third biosimilar, Insulin developed diagnostics, vaccines and Glargine, in the U.S. and obtained regulatory therapies to tilt the battle in favor of approvals for key biosimilars Bevacizumab and humanity. Insulin Aspart in the European Union. Our biosimilars benefited 3.1 million paents during India has been at the forefront of this the year. crusade, producing cost-effective As the only company from India to have three vaccines at scale for millions of people. biosimilars commercialized in the U.S. and among At the same time, the country has the select few globally to have five biosimilars approved in Europe, we are confident of enabling continued to supply the world with affordable access to expensive biologic drugs for generic and biosimilar therapies to millions of paents globally.
    [Show full text]
  • Annual-Report-1.Pdf
    p Composite Default screen Cover.prn D:\SUN BACK UP\Sun annula report-03-04\H8532 COVER and BK Aws.cdr Monday, August 22, 2005 12:23:20 PM p Composite Default screen Inside Ft.prn D:\SUN BACK UP\Sun annula report-03-04\H8532 COVER and BK Aws.cdr Monday, August 22, 2005 12:25:28 PM Color profile: Disabled Composite 175 lpi at 45 degrees A female bias for the blues? For long, scientists have observed that women are more vulnerable to depression. For long, this has been attributed by turns to an excitable nervous system, the opposing tugs of work and family. Researchers are now looking for a scientific reason for this discrepancy and it may be because of genes. Scientists say that depression in women is a global phenomenon cutting across class divides, spanning life experiences. Several genes, along with the surges in hormones may influence brain chemistry and trigger The cover shows 2 images from breakthroughs in depression. A risk factor linked to ruminating, over thinking, mulling over issues and re- neuroscience: a neuron, an MRI scan. living sad incidents is more common in women and could lead on to depression. However, half the risk could be genetic, with areas that cause this deep sadness now Two ideas that took learning from one field,and in an identified. And these genes act in concert with estrogen receptors with variations in sex inspired moment, “a flash of lightening” showed hormones in a complex interplay of hormones, neurotransmitters and receptor how best they could be applied to another field, activation.
    [Show full text]
  • No. 31015/68/2017-Pricing GOVERNMENT of INDIA MINISTRY of CHEMICALS & FERTILIZERS DEPARTMENT of PHARMACEUTICALS ………
    No. 31015/68/2017-Pricing GOVERNMENT OF INDIA MINISTRY OF CHEMICALS & FERTILIZERS DEPARTMENT OF PHARMACEUTICALS ……….. A Wing, Shastri Bhawan, New Delhi 110 001 Subject: Two review applications of M/s Abbott Healthcare Pvt. Limited against price fixation of their formulations “Sodium Valproate - CR Tablets 300mg and Sodium Valproate - CR Tablets 500mg” vide NPPA order No. S.O. 1687(E), dated 24.05.2017 issued under Drugs (Prices Control) Order, 2013 (DPCO 2013). Ref: 1) Two review applications, both dated 16.06.2017 2) NPPA notification under review S.O. No.1687(E), dated 24.05.2017 3) Record Note of discussions held in the personal hearing on 10.10.2017. 1. These are two petitions under paragraph 31 of the Drugs (Prices Control) Order, 2013 (hereinafter called the DPCO) filed by M/s Abbott Healthcare Pvt. Limited (hereinafter called the petitioner) against notification S.O. No.1687(E), dated 24.05.2017 issued by the National Pharmaceutical Pricing Authority (hereinafter called the NPPA) fixing the ceiling price of their formulations Sodium Valproate - CR Tablets 300mg and Sodium Valproate - CR Tablets 500mg. 2. The petitioner has contended as under: (i) Company submitted that NPPA has not considered MAT value & PTR data of M/s Sun Pharma who is a major player in this molecule. (ii) M/s Sun Pharma’s data as per AWACS dataset as given below:- SKU Name Company Aug’15 PTR MAT VAL (RS.) Encorate Sun Pharma Laboratories 52.34 21,98,63,785 Chrono 300 mg Limited tablet 10 Encorate Sun Pharma Laboratories 83.90 29,69,90,018 Chrono 300 mg Limited tablet 10 (iii) In view of above, company requested to advise NPPA to correct the apparent variance in calculation.
    [Show full text]